Yissum - Research Development Company of the Hebrew University

Personalizing Risk Assessment and Treatment Decisions in Cancers

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

Cluster8

A unified method for the diagnosis and treatment of cancer based on the Expression of the Cancer Testis Antigen gene Family in Individuals. CTA genes are very active during cellular differentiation and growth and non-active otherwise. The biopsy is beeing tested. Big database.
Project ID : 19-2016-4283

Description of the technology

Application

No two cancers are the same, and it can be difficult to predict which tumors are slow-growing and which are likely to grow and spread to other parts of the body. Current medical society guidelines rely on cancer stage to determine cancer treatment. Conventional classification of cancer stages is based primarily on the size and location of the tumor and serves as an indicator of disease progression.

However, cancer stage alone does not reveal the aggressiveness of the tumor. In fact, two patients with the same cancer stage may have very different estimates of mortality risk when tumor aggressiveness is taken into account.

Our Innovation

The proprietary custom made prediction kit for the aggressiveness of a tumor assessing:

  • five-year risk of cancer-specific death
  • odds of metastasis to other organs
  • treatment type, intensity and duration

A unified method for the diagnosis and treatment of cancer based on the Expression of the Cancer Testis Antigen gene (CTA) Family in Individuals.

The Technology

The technology is based on identifying the expression signature of a unique set of genes of the Cancer Testis Antigen (CTA) Family within the tumor and applying a specially designed machine learning algorithm which applies a unique subset of CTA genes for each solid tumor type.

Application of our technology in over 15,000 individuals and more than 150 types of cancers has consistently demonstrated that it is sufficient to determine the existence and staging of all solid cancers tested, with almost perfect accuracy.

The Opportunity

The technology provides several scores for a specific tumor such as:

  • Staging, grading and tumor dynamics
  • Prediction of Overall Disease Free (ODF) and Overall Survival (OS) terms
  • Probability of metastasis to nearby glands
  • Treatment urgency
  • Estimation for treatment impact
  • Potential treatment targets

Future development may enable similar readouts using a blood test (vs. biopsied materials). Also, our technology enables identification of the most relevant CTA’s for targeting antibodies and potentially T-cells in a specific manner to the tumor.

Current Development Stage

TRL4 biopsies validated in cancer patients

Project manager

Mel Larrosa
VP Business Development Healthcare

Project researchers

Yoav Smith
HUJI, School of Medicine - IMRIC

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Diagnostic
  • Therapeutic
  • Other Medical/Health Related
  • Agro and Marine biotech
  • Anatomy, Pathology, Immunology, Physiology
  • Clinical Medicine
  • Life Science & Biotechnology
  • diagnostics

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.